Kit ELISA Interleukin-1beta sandwich (IL-1β) (dog): quantitative dosage of Canine IL-1β in serum, plasma, buffered solution or cell culture medium.
Accession number
Q28292
Dose range
10.97-8000 pg/ml
Sensitivity of the dosage
10 pg/ml
Calibration range
10 pg/ml to 8000 pg/ml
Dose
ELISA solid-phase sandwich
Brand
Invitrogen
Kit ELISA Interleukin-1beta sandwich (IL-1β) (dog): quantitative dosage of Canine IL-1β in serum, plasma, buffered solution or cell culture medium.
Kit ELISA Interleukin-1beta sandwich (IL-1β) (dog): quantitative dosage of Canine IL-1β in serum, plasma, buffered solution or cell culture medium. The test recognizes only natural and recombinant forms of canine IL-1β.
Method principle: This ELISA solid phase sandwich test (immuno-enzymatic dose) measures the amount of target bound between a pair of matched antibodies. A specific target antibody is pre-adsorbed into the wells of the supplied microplate. Samples, standards or controls are added to these wells and bind to immobilized antibodies (capture antibodies). The sandwich is formed by adding the second antibody (detection antibody), then a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of the target present in the original sample.
Rigorous validation: Each batch manufactured from this ELISA kit is checked for criteria such as sensitivity, specificity, accuracy and reproducibility from one batch to another (see the package leaflet for more information on validation).
The beta-interleukin-1 (IL-1 beta) is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive proform that accumulates in cytosol. The cleavage of pro-IL-1 beta in the active 17 kDa protein requires the activation of inflammasomas, which are multiprotein complexes that respond to pathogens, stress conditions and other hazard signals. Activation of the inflammasoma triggers the treatment of the precursor of caspase-1 in its active form, which in turn cleaves the pro-IL-1 beta. IL-1 beta does not have a signal sequence peptide for the conventional ER/Golgi pathway and is secreted along the caspase-1 via an alternative mechanism and understood incompletely. Although the beta-IL-1 is most often secreted as active, the secretion of the uncleavened protein can be detectable under certain biological conditions. The signals of the IL-1 beta through two receptors, IL-1RI and IL-1RII, both of which are shared with the IL-1 alpha. The activity of the IL-1 beta may be moderated by the IL-1 receptor antagonist (IL-1RA), a protein produced by many types of cells that blocks receptor binding by competitive inhibition. IL-1 beta plays an important role in defending the innate host by triggering the production of other proinflammatory cytokines in target cells and by triggering acute phase responses to infection and injury. High levels of d的IL-1 beta have been associated with many chronic inflammatory conditions of the beta-IL-1 neutralizing the potential therapeutic value of antibodies.